Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEPW) Short Interest Down 91.2% in February

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEPW) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 354 shares, a decline of 91.2% from the January 29th total of 4,007 shares. Based on an average trading volume of 16,117 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 16,117 shares, the days-to-cover ratio is currently 0.0 days.

Coeptis Therapeutics Stock Performance

Shares of COEPW traded down $0.00 during midday trading on Wednesday, hitting $0.01. 22,622 shares of the company’s stock traded hands, compared to its average volume of 19,515. Coeptis Therapeutics has a 1 year low of $0.00 and a 1 year high of $0.05. The firm’s fifty day moving average is $0.01 and its 200-day moving average is $0.02.

About Coeptis Therapeutics

Coeptis Therapeutics is a clinical‐stage biopharmaceutical company focused on developing novel therapies for neurodegenerative and neuroinflammatory disorders. The company’s proprietary platform is based on engineered analogs of small heat shock proteins designed to modulate cellular stress responses, reduce inflammation and protect neurons from degeneration. Coeptis’s lead program is being advanced in amyotrophic lateral sclerosis (ALS), with additional preclinical studies underway in conditions such as multiple sclerosis and other central nervous system diseases.

Using its heat shock protein analog technology, Coeptis seeks to address the underlying pathology of neurodegeneration rather than merely managing symptoms.